gms | German Medical Science

60. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie (DGNN)

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie

26. - 28.08.2015, Berlin

The endoplasmic reticulum (ER) chaperone Sigma receptor 1 in Alzheimer’s disease pathology

Meeting Abstract

Suche in Medline nach

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 60th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Berlin, 26.-28.08.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. Doc15dgnnP13

doi: 10.3205/15dgnn37, urn:nbn:de:0183-15dgnn378

Veröffentlicht: 25. August 2015

© 2015 Yamoah.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Alzheimer’s disease (AD) is characterized histopathologically by extracellular amyloid-β (Aβ) plaques and neurofibrillary tangles composed of abnormal tau protein. Besides these hallmarks certain reactive and inflammatory processes including the activation of the innate immune response are also evident.

The endoplasmic reticulum (ER) protein SigR1 has diverse cellular functions which include chaperone activities and the regulation of calcium signalling, synaptic transmission and inflammatory processes. Drugs targeting SigR1 have been shown to be neuroprotective in several disease models including SOD1 mice, a model for Amyotrophic lateral sclerosis (ALS). Recent reports also suggested a significant role of SigR1 in AD pathogenesis. In the present study we focused on the role of in AD pathology. We studied AD patient brain tissue, a transgenic AD mouse model and a cell culture model treated with pathogenic Aβ peptide. We found that SigR1 protein is abnormally modified in the brains of AD patients and mice and that neurotoxicity induced by Aβ involves altered ER structure and function. These findings support the notion that modification of SigR1 might be a therapeutic target in AD.

Note: J. Weis & A. Goswami contributed equally to this work.